Deal Watch: Bristol And Otsuka Pursue Oncolytic Virus Therapies Via Licensing Deals
Busy stretch before Christmas holidays sees two deals around oncolytic virus therapeutics, a Middle East partnership for Orexigen’s Contrave, immuno-oncology deals involving Pfizer and ElsaLys, and Roche and ImmuNext partnering to develop drugs targeting the VISTA pathway.
You may also be interested in...
Business development execs Patrick Schleck and Michael Crowley talk to Scrip about the company’s recent deals with Parvus, Jecure and Microbiotica in the inflammatory and autoimmune disease space.
Three years after setting out to turnaround BioInvent, company president & CEO Michael Oredsson explains how the company is developing its immunotherapy offering. With tumor associated myeloid cells, BioInvent secured a deal with Pfizer at the end of 2016, while it intends to go it alone with its regulatory T-cell approach.
Sun Pharmaceutical Industries Ltd, India’s biggest drug firm, has struck a $175m deal to buy the branded skin cancer drug Odomzo from Novartis, continuing a drive to bulk up on higher-margin specialty products in the face of stiff pricing pressure on the generic front.